Bellicum Pharmaceuticals Inc (BLCM) Expected to Announce Quarterly Sales of $180,000.00

Equities analysts expect that Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) will report sales of $180,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Bellicum Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $30,000.00 and the highest estimate coming in at $400,000.00. Bellicum Pharmaceuticals reported sales of -$70,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 357.1%. The firm is scheduled to announce its next earnings results on Tuesday, March 12th.

On average, analysts expect that Bellicum Pharmaceuticals will report full-year sales of $910,000.00 for the current fiscal year, with estimates ranging from $600,000.00 to $1.20 million. For the next fiscal year, analysts anticipate that the business will post sales of $4.17 million, with estimates ranging from $300,000.00 to $11.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Bellicum Pharmaceuticals.

Several equities research analysts have recently commented on BLCM shares. Zacks Investment Research downgraded Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. ValuEngine raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $12.28.

Several institutional investors have recently made changes to their positions in BLCM. JPMorgan Chase & Co. increased its stake in Bellicum Pharmaceuticals by 8.4% during the third quarter. JPMorgan Chase & Co. now owns 3,874,395 shares of the biopharmaceutical company’s stock worth $23,866,000 after acquiring an additional 300,816 shares during the last quarter. BlackRock Inc. increased its position in shares of Bellicum Pharmaceuticals by 10.2% during the third quarter. BlackRock Inc. now owns 3,431,193 shares of the biopharmaceutical company’s stock worth $21,137,000 after purchasing an additional 318,799 shares in the last quarter. Vanguard Group Inc increased its position in shares of Bellicum Pharmaceuticals by 1.2% in the 3rd quarter. Vanguard Group Inc now owns 1,947,842 shares of the biopharmaceutical company’s stock valued at $11,999,000 after acquiring an additional 23,410 shares during the period. Vanguard Group Inc. increased its position in shares of Bellicum Pharmaceuticals by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,947,842 shares of the biopharmaceutical company’s stock valued at $11,999,000 after acquiring an additional 23,410 shares during the period. Finally, Wasatch Advisors Inc. grew its position in Bellicum Pharmaceuticals by 4.3% during the 3rd quarter. Wasatch Advisors Inc. now owns 963,148 shares of the biopharmaceutical company’s stock worth $5,933,000 after purchasing an additional 39,324 shares during the period. Institutional investors and hedge funds own 56.64% of the company’s stock.

Shares of BLCM stock traded up $0.06 during mid-day trading on Friday, reaching $3.20. 277,800 shares of the stock traded hands, compared to its average volume of 336,653. The company has a current ratio of 8.01, a quick ratio of 8.01 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $136.15 million, a price-to-earnings ratio of -1.13 and a beta of 1.58. Bellicum Pharmaceuticals has a 1-year low of $2.74 and a 1-year high of $10.26.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.

Further Reading: What kind of dividend yield to CEF’s pay?

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit